Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract.

[1]  K. Bensalah,et al.  Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. , 2010, European urology.

[2]  F. Montorsi,et al.  Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. , 2009, The Journal of urology.

[3]  J. Epstein,et al.  Small Endoscopic Biopsies of the Ureter and Renal Pelvis: Pathologic Pitfalls , 2009, The American journal of surgical pathology.

[4]  K. Bensalah,et al.  Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. , 2009, The Journal of urology.

[5]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[6]  K. Bensalah,et al.  Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi‐institutional analysis of 1363 patients , 2009, BJU international.

[7]  P. O’Donnell,et al.  The Role of Chemotherapy in Upper Tract Urothelial Carcinoma , 2009, Advances in urology.

[8]  V. Kouloulias,et al.  Comprehensive Management of Upper Tract Urothelial Carcinoma , 2008, Advances in urology.

[9]  P. Tsai,et al.  Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. , 2008, European urology.

[10]  M. Amin,et al.  Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. , 2008, Advances in anatomic pathology.

[11]  M. Brausi,et al.  Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. , 2007, European urology.

[12]  F. Ito,et al.  Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. , 2007, The Journal of urology.

[13]  J. Raman,et al.  Management of patients with upper urinary tract transitional cell carcinoma , 2007, Nature Clinical Practice Urology.

[14]  Susan A. Murphy,et al.  Monographs on statistics and applied probability , 1990 .

[15]  C. Wood,et al.  Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? , 2006, BJU international.

[16]  H. Ozen,et al.  Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. , 2006, The Journal of urology.

[17]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Choung-Soo Kim,et al.  The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. , 2004, The Journal of urology.

[19]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.

[20]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[21]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[22]  M. Droller.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. , 2002, The Journal of urology.

[23]  M. Resnick,et al.  Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. , 2000, Urology.

[24]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[25]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[26]  G. Jakse,et al.  Computed tomography for detection and staging of transitional cell carcinoma of the upper urinary tract. , 1995, European urology.

[27]  R. Tibshirani,et al.  Monographs on statistics and applied probability , 1990 .

[28]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.